Blueprint Medicines Co. (NASDAQ:BPMC) Stock Position Raised by XTX Topco Ltd

XTX Topco Ltd lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 406.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,146 shares of the biotechnology company’s stock after buying an additional 8,946 shares during the quarter. XTX Topco Ltd’s holdings in Blueprint Medicines were worth $972,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Blueprint Medicines in the fourth quarter worth approximately $51,000. Headlands Technologies LLC bought a new stake in Blueprint Medicines in the fourth quarter worth $65,000. Covestor Ltd increased its position in Blueprint Medicines by 62.7% during the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock worth $85,000 after buying an additional 375 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in Blueprint Medicines during the fourth quarter valued at about $88,000. Finally, Van ECK Associates Corp lifted its position in shares of Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after buying an additional 363 shares during the last quarter.

Blueprint Medicines Stock Down 1.3 %

BPMC opened at $81.45 on Wednesday. The company has a market capitalization of $5.21 billion, a P/E ratio of -75.42 and a beta of 0.75. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm’s fifty day moving average price is $89.79 and its two-hundred day moving average price is $93.39. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on BPMC shares. Wedbush reissued an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 28th. Scotiabank started coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a report on Tuesday, April 8th. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Insider Buying and Selling at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the transaction, the director now owns 152,396 shares in the company, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now owns 18,270 shares of the company’s stock, valued at $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,358 shares of company stock valued at $2,583,187. 4.21% of the stock is currently owned by corporate insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.